The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.

The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.

Pharmaceutical compositions comprising a vehicle, a solubilizer, and a surfactant are disclosed to be used in conjunction with non-chemotherapeutic active pharmaceutical ingredients which are soluble in water but subject to hydrolysis to some extent. Such non-chemotherapeutic active pharmaceutical ingredients may include amitriptyline, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral solution. Other embodiments are directed towards methods of using and methods of making such formulations.

There is provided a fast dissolving solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.

The invention relates generally to circadian rhythm disorders and, more particularly, to the treatment or prevention of circadian rhythm disorders based on an individual's HCN1 genotype. One aspect of the invention provides a method of treating an individual for delayed sleep time comprising: determining or having determined from a biological sample of the individual that the individual has a GG genotype at the rs12188518 single nucleotide polymorphism (SNP) locus; and administering to the individual once daily before a target bedtime a dose of tasimelteon effective to advance the sleep time of the individual. Other genotypes related with circadian rhythm disorders are CC at rs11248864 and AA at rs72762058.

The invention relates generally to circadian rhythm disorders and, more particularly, to the treatment or prevention of circadian rhythm disorders based on an individual's HCN1 genotype. One aspect of the invention provides a method of treating an individual for delayed sleep time comprising: determining or having determined from a biological sample of the individual that the individual has a GG genotype at the rs12188518 single nucleotide polymorphism (SNP) locus; and administering to the individual once daily before a target bedtime a dose of tasimelteon effective to advance the sleep time of the individual. Other genotypes related with circadian rhythm disorders are CC at rs11248864 and AA at rs72762058.

Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof:

##STR00001##

wherein A, B, G, R.sup.1, R.sup.1b, R.sup.1c, R.sup.2 and X are as defined herein.

Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof:

##STR00001##

wherein A, B, G, R.sup.1, R.sup.1b, R.sup.1c, R.sup.2 and X are as defined herein.

Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.